151 related articles for article (PubMed ID: 38102114)
1. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.
Barbui T; Carobbio A; Thiele J; Gangat N; Rumi E; Rambaldi A; Vannucchi AM; Tefferi A;
Blood Cancer J; 2023 Dec; 13(1):187. PubMed ID: 38102114
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors.
Teng G; Zhou Y; Zhang Y; Hu N; Liu T; Han Y; Gao C; Zhang L; Bai J
Thromb Res; 2022 Apr; 212():38-43. PubMed ID: 35219930
[TBL] [Abstract][Full Text] [Related]
3. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
4. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
5. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
6. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D; Falchi L; Verstovsek S
Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
[TBL] [Abstract][Full Text] [Related]
8. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Passamonti F; Rumi E; Caramella M; Elena C; Arcaini L; Boveri E; Del Curto C; Pietra D; Vanelli L; Bernasconi P; Pascutto C; Cazzola M; Morra E; Lazzarino M
Blood; 2008 Apr; 111(7):3383-7. PubMed ID: 18187660
[TBL] [Abstract][Full Text] [Related]
9. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Triguero A; Pedraza A; Pérez-Encinas M; Mata-Vázquez MI; Vélez P; Fox L; Gómez-Calafat M; García-Delgado R; Gasior M; Ferrer-Marín F; García-Gutiérrez V; Angona A; Gómez-Casares MT; Cuevas B; Martínez C; Pérez R; Raya JM; Guerrero L; Murillo I; Bellosillo B; Hernández-Boluda JC; Sanz C; Álvarez-Larrán A;
Ann Hematol; 2022 Oct; 101(10):2231-2239. PubMed ID: 36042023
[TBL] [Abstract][Full Text] [Related]
10. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.
Cerquozzi S; Barraco D; Lasho T; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Dec; 7(12):662. PubMed ID: 29282357
[TBL] [Abstract][Full Text] [Related]
12. [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center].
Bai J; Shi H; Ai L; Zhang L; Zhou Y; Li Z; Zhao Y; Sheng M; Li D; Li H; Qian L; Mi Y; Xiao Z; Zheng Y; Yang R; Xue Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1364-8. PubMed ID: 26178350
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract][Full Text] [Related]
14. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Benevolo G; Elli EM; Bartoletti D; Latagliata R; Tiribelli M; Heidel FH; Cavazzini F; Bonifacio M; Crugnola M; Binotto G; D'Addio A; Tieghi A; Bergamaschi M; Caocci G; Polverelli N; Bossi E; Auteri G; Carmosino I; Catani L; Cuneo A; Krampera M; Lanza F; Lemoli RM; Vianelli N; Breccia M; Palumbo GA; Cavo M; Palandri F
Hematol Oncol; 2021 Aug; 39(3):409-418. PubMed ID: 33590502
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.
Bai J; Ai L; Zhang L; Yang FC; Zhou Y; Xue Y
Am J Hematol; 2015 Dec; 90(12):1116-21. PubMed ID: 26370613
[TBL] [Abstract][Full Text] [Related]
16. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
Garrote M; López-Guerra M; García-Pagán JC; Arellano-Rodrigo E; Ferrer-Marín F; Hernández-Boluda JC; Bellosillo B; Nomdedeu M; Hernández-Gea V; Triguero A; Guijarro F; Álamo J; Baiges A; Turon F; Colomer D; Cervantes F; Alvarez-Larrán A
Ann Hematol; 2024 Mar; 103(3):737-747. PubMed ID: 38263537
[TBL] [Abstract][Full Text] [Related]
17. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
[TBL] [Abstract][Full Text] [Related]
19. New and old prognostic factors in polycythemia vera.
Passamonti F
Curr Hematol Malig Rep; 2009 Jan; 4(1):19-24. PubMed ID: 20425434
[TBL] [Abstract][Full Text] [Related]
20. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
